Privigen boosts the immune system with beneficial immunoglobulin G antibodies that help raise platelet counts to prevent bleeding in people with chronic ITP who are 15 years of age or older.
Platelet count increased 150% within 7 days in 80.7% of patients (46 of 57)
The average platelet count increased the first day after the first Privigen infusion, before the second infusion. Duration of response was at least 8.8 days in 75% of patients.
*In a prospective, open label, single-arm multicenter study assessing the efficacy, safety, and tolerability of Privigen in 57 subjects with chronic ITP and a platelet count of 20 x 109/L or less. Dose was 1 g/kg on 2 consecutive days. Primary endpoint was elevation of patient count to at least 50 x 109/L within 7 days of infusion.
†At the time of the Privigen pivotal trial, chronic ITP was defined as lasting 6 months or longer, and the disease criteria for that study population followed the earlier (>6 months) definition of chronic ITP, which is different than the current ASH 2019 defined definition of 12 months.
These are not the only side effects possible; see the full prescribing information, including boxed warning, for a complete list of adverse reactions possible with treatment for each condition.
Call your doctor if you experience any side effects, or if you have any other questions or concerns.